BMBarbra S. Miller

Barbra S. Miller

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Barbra S. Miller has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Retroperitoneal calcifying fibrous tumor mimicking an adrenal tumor

    by Erica C. Prochaska, Andrew P. Sciallis, Barbra S. Miller

    Establishing the etiology of a retroperitoneal tumor may be difficult due to close proximity of multiple organs. Evaluation of retroperitoneal tumors often leads to surgery, many times to obtain a definitive diagnosis and rule out malignancy. Calcifying fibrous tumors (CFT) are very rare soft tissue tumors occurring most often in young patients. They are most often found arising in the thoracic cavity, mediastinum, abdominal cavity and extremities and usually have a benign clinical course. Macrocscopically, the tumors are well circumscribed and firm with a white-tan appearance. Histologically, CFT comprised a hypocellular proliferation of bland spindle cells, densely hyalinized collagen, chronic lymphoplasmacytic inflammation and dystrophic calcifications. Other considerations in the pathologic differential diagnosis include solitary fibrous tumor and inflammatory myofibroblastic tumor.


  • 5th International ACC Symposium: Surgical Considerations in the Treatment of Adrenocortical Carcinoma

    by Barbra S. Miller

    Significant progress has been made in the understanding of how surgical technique impacts outcome in patients with adrenal cancer. Current and future areas of investigation center on expanding the role of surgery in patients with locally recurrent or metastatic disease, use of neoadjuvant therapy as a bridge to surgery, the impact of formal lymphadenectomy on survival, and improved diagnosis, prognosis, and selection of patients for surgery and other treatments using morphomic analysis.


  • Outcomes of Total Thyroidectomy with Therapeutic Central and Lateral Neck Dissection with a Single Dose of Radioiodine in the Treatment of Regionally Advanced Papillary Thyroid Cancer and Effects on Serum Thyroglobulin

    by David T. Hughes, Barbra S. Miller, Mark S. Cohen, Gerard M. Doherty, Paul G. Gauger

    Achieving an undetectable serum thyroglobulin (Tg) level (<1.0 ng/mL) after surgical and radioiodine treatment for papillary thyroid cancer (PTC) is associated with low recurrence rates and has been termed biochemical remission. This study aimed to determine the effectiveness of total thyroidectomy with therapeutic central and lateral neck dissection for regionally advanced (T1–4bN1bM0) PTC with regard to posttreatment Tg levels. This is a single-institution retrospective cohort study of patients with regionally advanced PTC initially treated with total thyroidectomy and therapeutic levels 2–7 neck dissection from 2002 to 2012. Pathologic findings, complications, serum Tg levels, and outcomes were analyzed. Sixty-one patients were initially treated with total thyroidectomy and therapeutic central and lateral neck dissection for PTC involving the lateral cervical nodes (N1b). The median number of lymph nodes excised and positive was 27 (range 5–112) and 9 (range 1–67), respectively. Extranodal extension occurred in 48 %. Radioiodine was administered after surgery with a median total dose of 150 mCi (range 30–244 mCi). Recurrent or persistent cervical disease occurred in 8 (13 %) and 3 (5 %) patients, respectively, and required additional radioiodine treatment in 2 and reoperative neck dissection in 10. Three patients developed new distant metastasis, and 1 died during the median follow-up of 20 months (range 1–109 months). Undetectable unstimulated Tg (<1.0 ng/mL) without clinically detectable recurrence was experienced in 68 % of patients with initial treatment. Biochemical remission can be experienced in most patients presenting with regionally advanced PTC with total thyroidectomy and compartment based therapeutic neck dissection followed by a single dose of radioiodine.


  • Worsening Central Sarcopenia and Increasing Intra‐Abdominal Fat Correlate with Decreased Survival in Patients with Adrenocortical Carcinoma

    by Barbra S. Miller, Kathleen M. Ignatoski, Stephanie Daignault, Ceit Lindland, Megan Doherty, Paul G. Gauger, Gary D. Hammer, Stewart C. Wang, Gerard M. Doherty, The University of Michigan Analytical Morphomics Group

    Background Accurate prediction of survival from adrenocortical carcinoma (ACC) is difficult and current staging models are unreliable. Central sarcopenia as part of the cachexia syndrome is a marker of frailty and predicts mortality. This study seeks to confirm that psoas muscle density (PMD), lean psoas muscle area (LPMA), lumbar skeletal muscle index (LSMI), and intra-abdominal (IA) or subcutaneous fat (SC) can be used in combination to more accurately predict survival in ACC patients. Methods PMD, LPMA, IA, and SC fat were measured on serial CT scans of patients with ACC. Clinical outcome was correlated with quantitative data from patients with ACC and analyzed. A linear regression model was used to describe the relationship between PMD, LPMA, LSMI, IA, and SC fat, time to recurrence, and length of survival according to tumor stage. Results One hundred twenty-five ACC patients (94 females) were treated from 2005 to 2011. Significant morphometric predictors of survival include PMD, LPMA, and IA fat (p ≤ 0.0001, ≤0.0024, 2 increase in LPMA confers an 8 % lower hazard of death. LSMI does not change significantly between stages (p = 0.3196). Conclusion Decreased PMD, LPMA, and increased IA fat suggest decreased survival in ACC patients and correlate with traditional staging systems. A more precise prediction of survival may be achieved when staging systems and morphometric measures are used in combination. Serial measurements of morphometric data are possible. The rate of change of these variables over time may be more important than the absolute value.


  • A quantitative tool to assess degree of sarcopenia objectively in patients with hypercortisolism

    by Barbra S. Miller, Kathleen M. Ignatoski, Stephanie Daignault, Ceit Lindland, Paul G. Gauger, Gerard M. Doherty, Stewart C. Wang


  • A debate on laparoscopic versus open adrenalectomy for adrenocortical carcinoma

    by Francesco Porpiglia, Barbra S. Miller, Matteo Manfredi, Cristian Fiori, Gerard M. Doherty

    Adrenocortical cancer (ACC) is a rare disease that is difficult to treat. Surgery remains the primary treatment modality and the only chance for cure in these patients. Since the early 1990s, laparoscopic adrenalectomy (LA) has replaced open adrenalectomy (OA) as the gold standard for addressing adrenal disorders of benign origin; however, the oncologic effectiveness of laparoscopic adrenalectomy for resection of primary adrenocortical malignancies remains unclear. Since the initial consensus statement from the International Adrenal Cancer Symposium held in Ann Arbor, MI in 2003, a number of studies have investigated the question of equivalence of LA compared to OA for ACC. Several controversial topics were debated during the 3rd International Adrenal Cancer Symposium held in Wurzburg, Germany in 2011. This debate sought to review the advantages and disadvantages of OA versus LA and review findings of recent studies related to the topic. As all studies involving this topic have methodological flaws, some more than others, the results of each study must be interpreted with caution. In conclusion, this debate will undoubtedly continue well into the future; however, it is clear that an oncologically appropriate surgical resection is of the utmost importance for the treatment of ACC and there is only one chance to achieve this. Poor outcomes will result from inadequate surgery, whether performed by an open or laparoscopic approach. Therefore, there is no doubt that surgery for suspected ACC should only be performed in specialized centers.


  • An examination of recently revised differentiated thyroid cancer guidelines

    by Barbra S Miller, Gerard M Doherty

    To examine the most recent changes in published guidelines by various organizations for the treatment of patients with differentiated thyroid cancer. This document provides a comparison of recommendations for common topics currently found in available thyroid cancer care guidelines. Recent changes to guidelines have focused on controversial topics, including extent of thyroidectomy based on tumor size, prophylactic central neck dissection, use of radioactive iodine, and degree of thyrotropin suppression. Regional variations between guidelines exist. Adherence to thyroid cancer guidelines at national levels is less than ideal. Guidelines for the management of differentiated thyroid cancer should continue to reflect minor regional variations in thyroid cancer treatment based on factors unique to that population while remaining otherwise similar to ensure optimal state-of-the-art patient care and outcomes. In the future, individual patient molecular information will likely play an important role in assessing the risk of tumor recurrence and overall survival. Consideration of multiple patient and tumor factors will allow thyroid cancer specialists to use a risk-adapted approach to patient care, from both a surgical and medical standpoint, to ensure optimal patient outcomes on an individual basis and at a disease level.